drugset / Trial / NCT00433888

Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)

NCT00433888

Phase 3 Completed 179 enrolled Chugai Pharmaceutical
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will assess the efficacy and safety of intravenous R744 in renal anemia patients on hemodialysis.

Timeline

Start
2007-01
Primary completion
2008-07
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject methoxy polyethylene glycol-epoetin beta Protein / enzyme biologic 25 ug Intravenous
Subject methoxy polyethylene glycol-epoetin beta Protein / enzyme biologic 400 ug Intravenous

Indications

No indication recorded.